Lenalidomide Krka d.d.

RSS
Withdrawn

This medicine's authorisation has been withdrawn

lenalidomide
MedicineHumanWithdrawn
  • Application under evaluation
  • CHMP opinion
  • European Commission decision

Overview

On 8 June 2023, the European Commission withdrew the marketing authorisation for Lenalidomide Krka d.d. (lenalidomide) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, KRKA, d.d., Novo mesto, which notified the European Commission of its decision not to market the product in the EU for commercial reasons. 

Lenalidomide Krka d.d. was granted marketing authorisation in the EU on 11 February 2021 for the treatment of multiple myeloma, myelodysplastic syndromes and follicular lymphoma. The marketing authorisation was initially valid for a 5-year period. 

Lenalidomide Krka d.d. is a generic medicine of Revlimid. There are other generic medicinal products of Revlimid authorised and marketed in the EU. 

The European Public Assessment Report (EPAR) for Lenalidomide Krka d.d. is updated to indicate that the marketing authorisation is no longer valid.

български (BG) (328.92 KB - PDF)

View

español (ES) (261.29 KB - PDF)

View

čeština (CS) (306.79 KB - PDF)

View

dansk (DA) (259.24 KB - PDF)

View

Deutsch (DE) (272.07 KB - PDF)

View

eesti keel (ET) (239.19 KB - PDF)

View

ελληνικά (EL) (332.87 KB - PDF)

View

français (FR) (262.92 KB - PDF)

View

hrvatski (HR) (289.32 KB - PDF)

View

italiano (IT) (259.7 KB - PDF)

View

latviešu valoda (LV) (316.38 KB - PDF)

View

lietuvių kalba (LT) (298.84 KB - PDF)

View

magyar (HU) (231.4 KB - PDF)

View

Malti (MT) (312.79 KB - PDF)

View

Nederlands (NL) (265.95 KB - PDF)

View

polski (PL) (304.28 KB - PDF)

View

português (PT) (260.47 KB - PDF)

View

română (RO) (305.2 KB - PDF)

View

slovenčina (SK) (300.72 KB - PDF)

View

slovenščina (SL) (226.58 KB - PDF)

View

Suomi (FI) (191.78 KB - PDF)

View

svenska (SV) (256.36 KB - PDF)

View

Product information

български (BG) (3.09 MB - PDF)

View

español (ES) (2.4 MB - PDF)

View

čeština (CS) (2.6 MB - PDF)

View

dansk (DA) (2.33 MB - PDF)

View

Deutsch (DE) (2.42 MB - PDF)

View

eesti keel (ET) (2.23 MB - PDF)

View

ελληνικά (EL) (2.68 MB - PDF)

View

français (FR) (2.45 MB - PDF)

View

hrvatski (HR) (2.43 MB - PDF)

View

íslenska (IS) (2.37 MB - PDF)

View

italiano (IT) (2.27 MB - PDF)

View

latviešu valoda (LV) (2.36 MB - PDF)

View

lietuvių kalba (LT) (2.42 MB - PDF)

View

magyar (HU) (2.8 MB - PDF)

View

Malti (MT) (2.9 MB - PDF)

View

Nederlands (NL) (2.36 MB - PDF)

View

norsk (NO) (2.39 MB - PDF)

View

polski (PL) (2.49 MB - PDF)

View

português (PT) (2.41 MB - PDF)

View

română (RO) (2.72 MB - PDF)

View

slovenčina (SK) (2.11 MB - PDF)

View

slovenščina (SL) (2.35 MB - PDF)

View

Suomi (FI) (2.38 MB - PDF)

View

svenska (SV) (2.15 MB - PDF)

View
Latest procedure affecting product information: IB/0003
13/12/2021
icon globe

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

български (BG) (171.95 KB - PDF)

View

español (ES) (134.31 KB - PDF)

View

čeština (CS) (137 KB - PDF)

View

dansk (DA) (90.94 KB - PDF)

View

Deutsch (DE) (100.6 KB - PDF)

View

eesti keel (ET) (130.43 KB - PDF)

View

ελληνικά (EL) (180.32 KB - PDF)

View

français (FR) (126.81 KB - PDF)

View

hrvatski (HR) (152.18 KB - PDF)

View

íslenska (IS) (131.69 KB - PDF)

View

italiano (IT) (101.72 KB - PDF)

View

latviešu valoda (LV) (166.24 KB - PDF)

View

lietuvių kalba (LT) (120.11 KB - PDF)

View

magyar (HU) (156.76 KB - PDF)

View

Malti (MT) (134.5 KB - PDF)

View

Nederlands (NL) (95.84 KB - PDF)

View

norsk (NO) (97.98 KB - PDF)

View

polski (PL) (141.25 KB - PDF)

View

português (PT) (115.13 KB - PDF)

View

română (RO) (154.91 KB - PDF)

View

slovenčina (SK) (139.56 KB - PDF)

View

slovenščina (SL) (154.33 KB - PDF)

View

Suomi (FI) (140.5 KB - PDF)

View

svenska (SV) (98.04 KB - PDF)

View

български (BG) (271.46 KB - PDF)

View

español (ES) (170.99 KB - PDF)

View

čeština (CS) (237.64 KB - PDF)

View

dansk (DA) (165.41 KB - PDF)

View

Deutsch (DE) (167.56 KB - PDF)

View

eesti keel (ET) (151.86 KB - PDF)

View

ελληνικά (EL) (272.7 KB - PDF)

View

français (FR) (164.22 KB - PDF)

View

hrvatski (HR) (201.27 KB - PDF)

View

íslenska (IS) (176.31 KB - PDF)

View

italiano (IT) (206.38 KB - PDF)

View

latviešu valoda (LV) (221.59 KB - PDF)

View

lietuvių kalba (LT) (217.51 KB - PDF)

View

magyar (HU) (192.63 KB - PDF)

View

Malti (MT) (242.2 KB - PDF)

View

Nederlands (NL) (169.92 KB - PDF)

View

norsk (NO) (154.48 KB - PDF)

View

polski (PL) (217.89 KB - PDF)

View

português (PT) (168.82 KB - PDF)

View

română (RO) (281.4 KB - PDF)

View

slovenčina (SK) (206.02 KB - PDF)

View

slovenščina (SL) (191.03 KB - PDF)

View

Suomi (FI) (156.36 KB - PDF)

View

svenska (SV) (164.79 KB - PDF)

View

Product details

Name of medicine
Lenalidomide Krka d.d.
Active substance
lenalidomide hydrochloride hydrate
International non-proprietary name (INN) or common name
lenalidomide
Therapeutic area (MeSH)
  • Multiple Myeloma
  • Lymphoma, Follicular
  • Myelodysplastic Syndromes
Anatomical therapeutic chemical (ATC) code
L04AX04

Pharmacotherapeutic group

Immunosuppressants

Therapeutic indication

Multiple myeloma

Lenalidomide Krka d.d. as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation.

Lenalidomide Krka d.d. as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4.2) is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant.

Lenalidomide Krka d.d. in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy.

Myelodysplastic syndromes

Lenalidomide Krka d.d. as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate.

Follicular lymphoma

Lenalidomide Krka d.d. in combination with rituximab (anti-CD20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (Grade 1 – 3a).

Authorisation details

EMA product number
EMEA/H/C/005729

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see Generic and hybrid medicines.

Marketing authorisation holder
Krka, d.d., Novo mesto 

Krka, d.d., Novo mesto
Šmarješka cesta 6
8501 Novo mesto
Slovenia

Opinion adopted
10/12/2020
Marketing authorisation issued
11/02/2021
Revision
2

Assessment history

This page was last updated on

Share this page